Security Snapshot

Ascendis Pharma A/S - Common Stock (ASND) Institutional Ownership

CUSIP: 04351P101

13F Institutional Holders and Ownership History from Q1 2015 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

304

Shares (Excl. Options)

64,677,198

Price

$213.24

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
ASND on Nasdaq
Shares outstanding
61,152,075
Price per share
$228.73
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
64,677,198
Total reported value
$13,781,007,160
% of total 13F portfolios
0.02%
Share change
+112,234
Value change
+$36,599,194
Number of holders
304
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ASND - Ascendis Pharma A/S - Common Stock is tracked under CUSIP 04351P101.
  • 304 institutions reported positions in Q4 2025.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 304 to 24 between Q4 2025 and Q1 2026.
  • Reported value moved from $13,781,007,160 to $115,982,237.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 304 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 04351P101?
CUSIP 04351P101 identifies ASND - Ascendis Pharma A/S - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Ascendis Pharma A/S - Common Stock (ASND) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WESTFIELD CAPITAL MANAGEMENT CO LP 8.5% -7.8% $1,115,183,925 -$73,663,872 5,185,696 -6.2% Westfield Capital Management Company, L.P. 31 Dec 2025
FMR LLC 8% $745,602,004 4,646,943 FMR LLC 31 Mar 2025
JANUS HENDERSON GROUP PLC 7.8% -2.5% $859,467,360 -$20,821,968 4,323,059 -2.4% JANUS HENDERSON GROUP PLC 30 Sep 2025
Artisan Partners Limited Partnership 5.2% $687,887,717 3,225,885 Artisan Partners Asset Management Inc. 31 Dec 2025
Capital International Investors 5.6% $548,747,120 3,109,225 Capital International Investors 30 Jun 2025
T. Rowe Price Investment Management, Inc. 4.8% -27% $530,338,200 -$182,106,580 2,667,563 -26% T. Rowe Price Investment Management, Inc. 30 Sep 2025

As of 31 Dec 2025, 304 institutional investors reported holding 64,677,198 shares of Ascendis Pharma A/S - Common Stock (ASND). This represents 106% of the company’s total 61,152,075 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Ascendis Pharma A/S - Common Stock (ASND) together control 86% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 17% 10,281,496 0% 23% $2,192,426,207
WESTFIELD CAPITAL MANAGEMENT CO LP 8.5% 5,185,696 -1.4% 4.6% $1,105,797,733
Avoro Capital Advisors LLC 8.4% 5,111,111 +0.02% 11% $1,089,893,310
FMR LLC 6.8% 4,153,311 -7.1% 0.05% $885,651,945
JANUS HENDERSON GROUP PLC 6.6% 4,061,641 -6% 0.39% $866,104,326
Artisan Partners Limited Partnership 5.3% 3,225,885 -13% 1.1% $687,887,701
Capital International Investors 5% 3,063,943 +0.11% 0.1% $653,355,205
FRANKLIN RESOURCES INC 3.1% 1,910,079 +20% 0.1% $407,305,320
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 3.1% 1,886,393 +0.19% 0.13% $402,254,443
WELLINGTON MANAGEMENT GROUP LLP 2.9% 1,762,721 -2% 0.07% $375,882,627
T. Rowe Price Investment Management, Inc. 2.7% 1,667,625 -37% 0.22% $355,605,000
PRICE T ROWE ASSOCIATES INC /MD/ 2.6% 1,570,260 -9% 0.04% $334,843,000
AMERICAN CENTURY COMPANIES INC 2.4% 1,443,141 +165% 0.15% $307,736,614
PERCEPTIVE ADVISORS LLC 1.8% 1,081,421 -0.65% 4.2% $230,602,214
PRINCIPAL FINANCIAL GROUP INC 1.7% 1,026,407 +29% 0.11% $218,871,029
BlackRock, Inc. 1% 628,200 +39% 0% $133,957,368
MORGAN STANLEY 1% 617,968 +52% 0.01% $131,775,763
GOLDMAN SACHS GROUP INC 0.98% 596,703 -8.6% 0.02% $127,240,947
Invesco Ltd. 0.96% 586,094 -36% 0.02% $124,978,684
AMERIPRISE FINANCIAL INC 0.9% 550,477 -2.2% 0.03% $117,383,715
CITADEL ADVISORS LLC 0.85% 519,516 +1780% 0.08% $110,781,591
JPMORGAN CHASE & CO 0.83% 507,240 +73% 0.01% $108,163,857
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.81% 496,837 0% 0.16% $105,946,000
FIL Ltd 0.78% 478,641 +4.2% 0.08% $102,065,407
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.77% 470,951 0.14% $100,425,591

Institutional Holders of Ascendis Pharma A/S - Common Stock (ASND) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 507,073 $115,982,237 +$55,615,405 $228.73 24
2025 Q4 64,677,198 $13,781,007,160 +$36,599,194 $213.24 304
2025 Q3 63,798,487 $12,683,838,954 +$232,138,786 $198.81 279
2025 Q2 62,895,390 $10,855,906,781 -$373,773,069 $172.60 245
2025 Q1 65,180,066 $10,147,446,038 +$223,136,493 $155.86 241
2024 Q4 63,751,521 $8,776,308,689 +$115,863,512 $137.67 212
2024 Q3 62,595,716 $9,312,956,409 +$237,478,312 $149.31 218
2024 Q2 60,687,245 $8,276,478,215 -$25,623,552 $136.38 202
2024 Q1 60,791,422 $9,189,438,728 +$198,420,492 $151.17 188
2023 Q4 60,262,338 $7,590,188,894 -$95,295,592 $125.95 183
2023 Q3 60,279,508 $5,644,577,484 -$61,738,785 $93.64 157
2023 Q2 61,039,136 $5,447,708,812 -$42,606,636 $89.25 156
2023 Q1 60,982,797 $6,535,152,679 -$603,913,240 $107.22 160
2022 Q4 65,956,055 $8,054,269,679 -$66,421,048 $122.13 183
2022 Q3 66,716,414 $6,891,080,476 +$149,538,106 $103.26 177
2022 Q2 63,211,628 $5,875,622,934 +$99,259,708 $92.96 162
2022 Q1 61,928,932 $7,267,064,424 +$416,027,513 $117.36 169
2021 Q4 58,376,386 $7,851,336,290 -$60,447,865 $134.53 168
2021 Q3 58,008,737 $9,244,880,979 +$506,030,857 $159.39 162
2021 Q2 55,049,436 $7,239,726,130 +$277,622,452 $131.55 167
2021 Q1 52,687,197 $6,790,538,552 -$259,999,867 $128.88 172
2020 Q4 54,357,110 $9,065,494,890 +$123,538,090 $166.78 173
2020 Q3 53,548,292 $8,263,618,101 +$776,855,285 $154.32 150
2020 Q2 48,248,343 $7,132,005,530 +$39,025,561 $147.90 149
2020 Q1 47,871,754 $5,391,239,456 +$191,350,357 $112.61 143
2019 Q4 46,149,738 $6,420,287,137 -$13,680,500 $139.12 139
2019 Q3 46,122,563 $4,442,511,426 -$194,325,083 $96.32 127
2019 Q2 47,663,417 $5,487,484,115 +$237,283,765 $115.15 132
2019 Q1 45,989,019 $5,412,737,939 +$716,635,309 $117.70 137
2018 Q4 40,100,469 $2,509,199,237 -$10,826,186 $62.65 102
2018 Q3 40,188,306 $2,847,498,166 +$44,455,437 $70.86 94
2018 Q2 39,572,750 $2,632,379,192 +$96,237,781 $66.52 100
2018 Q1 38,126,373 $2,493,396,132 +$345,130,853 $65.40 89
2017 Q4 30,513,340 $1,222,363,447 +$50,139,269 $40.06 64
2017 Q3 28,774,674 $1,042,816,000 +$204,057,698 $36.25 59
2017 Q2 23,269,447 $646,000,000 +$80,276,736 $27.76 34
2017 Q1 20,898,775 $585,169,000 +$9,050,400 $28.00 34
2016 Q4 20,561,240 $416,160,000 +$130,784,664 $20.24 31
2016 Q3 13,995,656 $281,311,000 +$4,791,129 $20.10 22
2016 Q2 13,876,594 $184,147,000 +$10,182,326 $13.27 23
2016 Q1 12,036,579 $223,242,000 +$9,842,726 $18.55 25
2015 Q4 10,090,990 $184,865,000 +$7,675,460 $18.32 24
2015 Q3 8,925,979 $157,986,000 -$15,929 $17.70 24
2015 Q2 8,953,630 $157,820,000 +$7,731,541 $17.68 32
2015 Q1 8,477,992 $145,818,000 +$145,818,000 $17.35 35